

Supplementary Table 2: Meta-analytic results for variance ratios and coefficients of variance ratios, individual AD, only studies reporting pre-post-differences

	n			Variance Ratio (VR) Meta-Analysis			r (M, SD)		Coefficient of Variance Ratio (CVR) Meta-Analysis		
	Trials	AD	Placebo	VR (95% CI)	p	Q(df)	AD	Placebo	CVR (95% CI)	P	Q (df)
Agomelatine	0	-	-	-	-	-	-	-	-	-	-
Amitriptyline	11	754	771	1.04 (0.95-1.14)	.40	15.80 (10)	-.34	.64*	0.65(0.58-0.72)	.00	6.96 (10)
Bupropion	13	2095	1887	0.99 (0.94-1.03)	.99	2.57 (12)	.89**	.87**	0.88 (0.82-0.94)	.00	7.70 (12)
Citalopram	11	1819	1335	1.02 (0.97-1.07)	.50	4.35 (10)	.54**	.71*	0.85 (0.79-0.92)	.00	4.83 (10)
Clomipramine	0	-	-	-	-	-	-	-	-	-	-
Desvenlafaxine	7	2124	1241	1.00 (0.95-1.05)	.91	1.17 (6)	-.05	-.03	0.83 (0.77-0.89)	.00	1.33 (6)
Duloxetine	20	2953	2371	1.01 (0.97-1.05)	.66	1.81 (19)	.61**	.73**	0.76 (0.71-0.81)	.00	25.63 (19)
Escitalopram	16	2749	2114	1.06 (0.95-1.19)	.28	74.54 (15)** ^a	.65**	.05	0.90 (0.79-1.02)	.11	55.82 (15)**
Fluoxetine	18	2765	1991	1.00 (0.96-1.05)	.95	6.96 (17)	.60**	.71**	0.85 (0.78-0.92)	.00	20.58(17)
Fluvoxamine	0	-	-	-	-	-	-	-	-	-	-
Levomilnacipran	5	1566	1032	1.03 (0.97-1.09)	.31	2.91 (4)	.20	.45	0.83 (0.74-0.92)	.00	6.02 (4)
Milnacipran	0	-	-	-	-	-	-	-	-	-	-
Mirtazapine	10	624	466	1.00 (0.91-1.09)	.96	8.74 (9)	.52	.35	0.72 (0.63-0.83)	.00	10.91 (9)
Nefazodone	9	767	528	1.01 (0.97-1.09)	.90	0.34 (8)	.27	-.29	0.80 (0.71-0.91)	.00	5.09 (8)
Paroxetine	37	4233	3333	1.00 (0.97-1.04)	.89	11.27 (36)	.28	.26	0.82 (0.78-0.86)	.00	41.51 (36)
Reboxetine	6	1035	944	0.99 (0.93-1.05)	.69	0.45 (5)	.51	.66	0.92 (0.79-1.07)	.28	12.10 (5)*
Sertraline	15	1534	1374	0.98 (0.90-1.06)	.57	27.03 (14)	.75**	.77**	0.77 (0.71-0.83)	.00	11.68 (14)
Trazodone	0	-	-	-	-	-	-	-	-	-	-

	n			Variance Ratio (VR) Meta-Analysis			r (M, SD)		Coefficient of Variance Ratio (CVR) Meta-Analysis		
Venlafaxine	16	2292	1798	0.99 (0.95-1.04)	.82	6.64 (15)	.36	.18	0.80 (0.75-0.85)	.00	11.86 (15)
Vilazodone	5	1360	1064	0.99 (0.93-1.05)	.72	1.07 (4)	.55	.28	0.81 (0.73-0.90)	.00	4.96 (4)
Vortioxetine	14	3562	2098	1.00 (0.96-1.04)	.99	0.41 (13)	.32	.79**	0.81 (0.76-0.88)	.00	23.04 (13)*

Notes:

r (M, SD) is the Pearson correlation coefficient of mean pre-post differences in depression (M) and the respective standard deviation (SD). Q(df) is the heterogeneity index of the meta-analysis. In case of AD without trials that reported pre-post differences, the results for the post-values of depression scores also resulted in VR \approx 1.00 (Agomelatine: VR = 0.96, CI 0.92-1.01; Fluvoxamine VR = 0.99, CI 0.88-1.12; Trazodone: VR = 0.96, CI 0.88-1.06. For Clomipramine and Milnacipran, no placebo-controlled trials were available.

* p < .05, ** p < .01

^aThis result was caused by an outlier (Study Dube 2010, NCT00420004), and after removing this study, the heterogeneity index was Q(df=14)=7.36, p = 0.92.